The role of the microbiome in NAFLD and NASH
Open accessThe DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly becoming the most prevalent liver disease worldwide. A sizable minority of NAFLD patients develop nonalcoholic steatohepatitis (NASH), which is characterized by inflammatory changes that can lead to progressive liver damage, cirrhosis, and hepatocellular carcinoma. Recent studies have shown that in addition to genetic predisposition and diet, the gut microbiota affects hepatic carbohydrate and lipid metabolism as well as influences the balance between pro‐inflammatory and anti‐inflammatory effectors in the liver, thereby impacting NAFLD and its progression to NASH. In this review, we will explore the impact of gut microbiota and microbiota‐derived compounds on the development and progression of NAFLD and NASH, and the unexplored factors related to potential microbiome contributions to this common liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activation of these TLRs can contribute to the development of NAFLD and nonalcoholic steatohepatitis (NASH), with the most extensively studied pathway being LPS-TLR4 signaling.180”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245 · cited 2×
“However, conven-tionalization of germ-free mice with normal mouse microbiota induces de novo hepatic lipogenesis, in addition to increased body fat content and insulin resistance (Ba¨ckhed et al , 2004).”
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Intestinal mucosal barrier function in health and disease
Turner, J. R. (2009) · Nature reviews. Immunology · doi:10.1038/nri2653 · Cited by 3,952 · cited 1×
“Under physiological conditions, tight junction proteins, such as zonula occludens, seal adjacent epithelial cells at the apical sites and prevent bacteria from entering the intestinal mucosa and the bloodstream (Turner, 2009).”
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 1×
“…in the digestion of food and facilitates the absorption of the dietary molecules into the portal and systemic circulation (Jumpertz et al , 2011; Ridaura et al , 2013), interacts with the mucosal immune system, to shape development of its antigen recognition, recruitment, proliferation, and…”
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., Schilter, H. C., Rolph, M. S., Mackay, F., Artis, D., et al. (2009) · Nature · doi:10.1038/nature08530 · Cited by 3,241 · cited 3×
“In addition, SCFAs are also potent signaling molecules through binding to G-protein-coupled receptors GPR41, GPR43, and GPR109A (Samuel et al , 2008; Maslowski et al , 2009).”
Research works printed but not linked: 1
- Ackermann D, Schutze H (1910) The formation of trimethylamine by bacterium prodigiosum. Zentralb Physiol 24: 210–211
Cited by
Items 101–200 of 548
The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity
Fu, K., Wang, C., Ma, C., Zhou, H., & Li, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.771459 · Cited by 60
Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease
Philips, C. A., Augustine, P., Yerol, P. K., Ramesh, G. N., Ahamed, R., Rajesh, S. K., George, T., & Kumbar, S. V. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00035 · Cited by 60
Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease
Steensels, S., Qiao, J., & Ersoy, B. A. (2020) · Metabolites · doi:10.3390/metabo10070283 · Cited by 58
Ni, Y., Ni, L., Zhuge, F., & Fu, Z. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000375 · Cited by 57
Omega-3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease
Shama, S., & Liu, W. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06117-5 · Cited by 53
Crosstalk between PPARs and gut microbiota in NAFLD
Wu, L., Li, J., Feng, J., Ji, J., Yu, Q., Li, Y., Zheng, Y., Dai, W., Wu, J., & Guo, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111255 · Cited by 53
He, L., Yao, D.-H., Wang, L., Zhang, L., & Bai, X. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.761836 · Cited by 56
Zhao, M., Chen, S., Ji, X., Shen, X., You, J., Liang, X., Yin, H., & Zhao, L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105517 · Cited by 53
Systemic Immunoregulatory Consequences of Gut Commensal Translocation
McPherson, A. C., Pandey, S. P., Bender, M. J., & Meisel, M. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.12.005 · Cited by 49
Shen, B., Gu, T., Shen, Z., Zhou, C., Guo, Y., Wang, J., Li, B., Xu, X., Li, F., Zhang, Q., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.08.001 · Cited by 51
Zhang, X., Lau, H. C.-H., Ha, S., Liu, C., Liang, C., Lee, H. W., Ng, Q. W.-Y., Zhao, Y., Ji, F., Zhou, Y., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-024-01177-7 · Cited by 53
Yue, S., Tan, Y.-Y., Zhang, L., Zhang, B., Jiang, F.-Y., Ji, G., Liu, B., & Wang, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.885039 · Cited by 51
Sex, Nutrition, and NAFLD: Relevance of Environmental Pollution
Dolce, A., & Torre, S. D. (2023) · Nutrients · doi:10.3390/nu15102335 · Cited by 51
Zeng, F., Su, X., Liang, X., Liao, M., Zhong, H., Xu, J., Gou, W., Zhang, X., Shen, L., Zheng, J., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03317-y · Cited by 50
The Potential Role of Probiotics in Protection against Influenza a Virus Infection in Mice
Lu, W., Fang, Z., Liu, X., Li, L., Zhang, P., Zhao, J., Zhang, H., & Chen, W. (2021) · Foods · doi:10.3390/foods10040902 · Cited by 51
Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
dos Santos, J. P. M., de Maio, M. C., Lemes, M. A., Laurindo, L. F., Haber, J. F. D. S., Bechara, M. D., do Prado, P. S., Rauen, E. C., Costa, F., Pereira, B. C. D. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010498 · Cited by 56
Hong, J. T., Lee, M.-J., Yoon, S. J., Shin, S. P., Bang, C. S., Baik, G. H., Kim, D. J., Youn, G. S., Shin, M. J., Ham, Y. L., et al. (2020) · Journal of Ginseng Research · doi:10.1016/j.jgr.2020.07.004 · Cited by 50
Leung, H., Xiong, L., Ni, Y., Busch, A., Bauer, M. W., Press, A. T., & Panagiotou, G. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00398-0 · Cited by 49
Fogacci, F., Giovannini, M., Micoli, V. D., Grandi, E., Borghi, C., & Cicero, A. F. G. (2024) · Nutrients · doi:10.3390/nu16152454 · Cited by 50
The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease
Ni, Y., Lu, M., Xu, Y., Wang, Q., Gu, X., Li, Y., Zhuang, T., Xia, C., Zhang, T., Gou, X., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.908011 · Cited by 48
Yi, X., Ren, M., Yang, J., Cai, C., Cheng, W., Zhou, X., Lu, D., & Ji, F. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1003755 · Cited by 48
The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease
Filipović, B. F., Lukić, S., Mijac, D. D., Marjanovic-Haljilji, M., Vojnović, M., Bogdanović, J. M., Glišić, T., Filipović, N., Kiswani, J. A., Djoković, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413219 · Cited by 46
Fgf21-Dubosiella axis mediates the protective effects of exercise against NAFLD development
Ye, X., Sun, P., Lao, S., Wen, M., Zheng, R., Lin, Y., Gan, L., Fan, X., Wang, P., Li, Z., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122231 · Cited by 46
Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis
Yang, R., Shang, J., Zhou, Y., Liu, W., Tian, Y., & Shang, H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2016391 · Cited by 43
Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions
Wei, M., Tu, W., & Huang, G. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1341938 · Cited by 46
Zhang, C., Xiao, Q., Sheng, J., Liu, T., Cao, Y.-Q., Xue, Y., Shi, M., Cao, Z., Zhou, L.-F., Luo, X., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110076 · Cited by 44
Lim, J. J., Li, X., Lehmler, H., Wang, D., Gu, H., & Cui, J. Y. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa090 · Cited by 45
Pfohl, M., Marques, E., Auclair, A., Barlock, B., Jamwal, R., Goedken, M., Akhlaghi, F., & Slitt, A. L. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfaa172 · Cited by 43
Han, Y., Li, L., & Wang, B. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0960-z · Cited by 44
Intestinal α1-2-Fucosylation Contributes to Obesity and Steatohepatitis in Mice
Zhou, R., Llorente, C., Cao, J., Zaramela, L. S., Zeng, S.-L., Gao, B., Li, S., Welch, R. D., Huang, F., Qi, L., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.02.009 · Cited by 44
Gut dysbiosis and metabolic diseases
Bandopadhyay, P., & Ganguly, D. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.06.031 · Cited by 46
Germ‐free mice are not protected against diet‐induced obesity and metabolic dysfunction
Moretti, C. H., Schiffer, T. A., Li, X., Weitzberg, E., Carlström, M., & Lundberg, J. O. (2021) · Acta Physiologica · doi:10.1111/apha.13581 · Cited by 37
Ji, D., Chen, G.-F., Niu, X.-X., Zhang, M., Wang, C., Shao, Q., Wu, V., Wang, Y., Cheng, G. Y.-M., Hurwitz, S. J., et al. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100090 · Cited by 46
Convertini, P., Santarsiero, A., Todisco, S., Gilio, M., Palazzo, D., Pappalardo, I., Iacobazzi, D., Frontuto, M., & Infantino, V. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04431-w · Cited by 43
Chen, L., Zhang, L., Wang, W., Qiu, W., Liu, L., Ning, A., Cao, J., Huang, M., & Zhong, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232972 · Cited by 41
Wijarnpreecha, K., Panjawatanan, P., Cheungpasitporn, W., Lukens, F., Harnois, D. M., Pungpapong, S., & Ungprasert, P. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-841 · Cited by 41
Luo, X., Zhang, B., Pan, Y., Gu, J., Tan, R., & Gong, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.893561 · Cited by 47
Crucial functions of gut microbiota on gut–liver repair
Wang, Y., Yan, H., Zheng, Q., & Sun, X. (2025) · hLife · doi:10.1016/j.hlife.2025.01.001 · Cited by 42
Serum Ferritin Correlates With Liver Fat in Male Adolescents With Obesity
Mörwald, K., Aigner, E. S., Bergsten, P., Brunner, S. M., Forslund, A. H., Kullberg, J., Ahlström, H. K., Manell, H., Roomp, K., Schütz, S., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00340 · Cited by 40
Bilson, J., Sethi, J. K., & Byrne, C. D. (2021) · Proceedings of The Nutrition Society · doi:10.1017/s0029665121003815 · Cited by 44
Gut microbial response to host metabolic phenotypes
Hou, J., Xiang, J., Li, D., Liu, X., & Pan, W. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1019430 · Cited by 40
Endometriosis and dysbiosis: State of art
Zizolfi, B., Foreste, V., Gallo, A., Martone, S., Giampaolino, P., & Sardo, A. D. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1140774 · Cited by 41
Yu, L., Gao, F., Li, Y., Su, D., Han, L., Li, Y., Zhang, X., & Feng, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116724 · Cited by 41
Mechanistic insights into the liver–brain axis during chronic liver disease
Siddle, M. R., Durán, R. G., Goel, D., Renquist, B. J., Holt, M. K., & Hadjihambi, A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01142-z · Cited by 41
Scarpellini, E., Fagoonee, S., Rinninella, E., Rasetti, C., Aquila, I., Larussa, T., Ricci, P., Luzza, F., & Abenavoli, L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082488 · Cited by 43
The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD
Huang, W., & Kong, D. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111235 · Cited by 41
Zhang, Z., Chen, X., & Cui, B. (2021) · Food & Function · doi:10.1039/d1fo00249j · Cited by 40
The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis
Xiang, H., Sun, D., Liu, X., She, Z., & Chen, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.812610 · Cited by 40
Retinoids in the Pathogenesis and Treatment of Liver Diseases
Melis, M., Tang, X., Trasino, S. E., & Gudas, L. J. (2022) · Nutrients · doi:10.3390/nu14071456 · Cited by 40
Gorelick, J., Assa-Glazer, T., Zandani, G., Altberg, A., Sela, N., Nyska, A., & Madar, Z. (2022) · Journal of Cannabis Research · doi:10.1186/s42238-022-00137-w · Cited by 40
The immune response as a therapeutic target in non-alcoholic fatty liver disease
Ortiz‐López, N., Fuenzalida, C., Dufeu, M. S., Pinto-León, A., Escobar, A. F., Poníachik, J., Roblero, J. P., Valenzuela-Pérez, L., & Beltrán, C. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954869 · Cited by 40
Bacteroides and NAFLD: pathophysiology and therapy
Zhang, J., Zhou, J., He, Z., & Li, H. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1288856 · Cited by 44
Gut microbiota in mental health and depression: role of pre/pro/synbiotics in their modulation
Methiwala, H. N., Vaidya, B., Addanki, V. K., Bishnoi, M., Sharma, S. S., & Kondepudi, K. K. (2021) · Food & Function · doi:10.1039/d0fo02855j · Cited by 41
Hamady, S., Eissa, S., Ghanem, H., Ahmed, E. K., Hasanin, A. H., Mahdy, M. M. E., & Matboli, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111781 · Cited by 38
Shao, G., Liu, Y., Lu, L., Zhang, G., Zhou, W., Wu, T., Wang, L., Xu, H., & Ji, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944088 · Cited by 39
Kabbani, M., Michailidis, E., Steensels, S., Fulmer, C. G., Luna, J. M., Pen, J. L., Tardelli, M., Razooky, B. S., Ricardo-Lax, I., Zou, C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111321 · Cited by 38
Ghosh, S., Yang, X., Wang, L., Zhang, C., & Zhao, L. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.12.011 · Cited by 38
Platelets in Non-alcoholic Fatty Liver Disease
Dalbeni, A., Castelli, M., Zoncapè, M., Minuz, P., & Sacerdoti, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.842636 · Cited by 41
Liao, J., Cao, Y., Zhao, J., Yu, B., Wang, Y., Li, W., Li, H., Lv, S., Wen, W., Cui, H., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154937 · Cited by 37
Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
Filipović, B. F., Marjanovic-Haljilji, M., Mijac, D. D., Lukić, S., Kapor, S., Kapor, S., Starčević, A., Popovic, D. D., & Djoković, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110573 · Cited by 37
Discovery of robust and highly specific microbiome signatures of non-alcoholic fatty liver disease
Nychas, E., Marfil-Sánchez, A., Chen, X., Mirhakkak, M. H., Li, H., Jia, W., Xu, A., Nielsen, H. B., Nieuwdorp, M., Loomba, R. S., et al. (2025) · Microbiome · doi:10.1186/s40168-024-01990-y · Cited by 36
Bahitham, W., Banoun, Y., Aljahdali, M., Almuaiqly, G., Bahshwan, S. M., Aljahdali, L., Sanai, F. M., Rosado, A. S., & Sergi, C. M. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1637071 · Cited by 41
Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH
Hegazy, M., Mogawer, S., Alnaggar, A. R., Ghoniem, O. A., & Samie, R. M. A. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s249949 · Cited by 38
Zhu, M., Wang, X., Wang, K., Zhao, Z., Dang, Y., Ji, G., Li, F., & Zhou, W. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1066053 · Cited by 36
Carr, R. M., Li, Y., Chau, L., Friedman, E. S., Lee, J., Adorini, L., Erickson, M., Zaru, L., Shringarpure, R., MacConell, L., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000474 · Cited by 36
Chen, P., Yang, C., Ren, K., Xu, M., Pan, C., Ye, X., & Li, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1504948 · Cited by 38
Abdelhameed, F., Mustafa, A., Kite, C., Lagojda, L., Dallaway, A., Than, N. N., Kassi, E. N., Kyrou, I., & Randeva, H. S. (2025) · Livers · doi:10.3390/livers5010011 · Cited by 37
Nonalcoholic fatty liver disease and colorectal cancer: Correlation and missing links
Chakraborty, D., & Wang, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118507 · Cited by 36
The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis
LeBlanc, J., Segal, J. P., Braz, L. M. D. C., & Hart, A. L. (2021) · Nutrients · doi:10.3390/nu13061780 · Cited by 36
Shen, B., Wang, J., Guo, Y., Gu, T., Shen, Z., Zhou, C., Li, B., Xu, X., Li, F., Zhang, Q., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.756299 · Cited by 35
Nozu, T., & Okumura, T. (2022) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm21002 · Cited by 35
Ciardullo, S., Rea, F., Savaré, L., Morabito, G., Perseghin, G., & Corrao, G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac231 · Cited by 37
Yan, M., Man, S., Ma, L., & Gao, W. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155264 · Cited by 35
Tan, Y., Huang, Z., Liu, Y., Li, X., Stalin, A., Fan, X., Wu, Z., Wu, C., Lu, S., Zhang, F., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116418 · Cited by 34
Dobbie, L. J., Burgess, J., Hamid, A., Nevitt, S. J., Hydes, T., Alam, U., & Cuthbertson, D. J. (2024) · Nutrients · doi:10.3390/nu16071030 · Cited by 37
Romanos, M., Cordova, J. M. G., Villamarin, J. L., Zurita, J. D. P., & Acosta, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70659 · Cited by 35
Yan, S., Tian, S., Meng, Z., Teng, M., Sun, W., Jia, M., Zhou, Z., Bi, S., & Zhu, W. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.116306 · Cited by 34
Qin, S., Wang, Y., Wang, S., Ning, B., Huai, J., & Yang, H. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.870422 · Cited by 35
Chen, X., Liu, M., Tang, J., Wang, N., Feng, Y., & Ma, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911710 · Cited by 36
Guo, J., Wang, P., Cui, Y., Hu, X., Chen, F., & Ma, C. (2023) · Nutrients · doi:10.3390/nu15041043 · Cited by 35
Gut‑liver axis in liver disease: From basic science to clinical treatment (Review)
Wang, J., Wang, X., Zhuo, E., Chen, B., & Chan, S. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13375 · Cited by 35
Markowska, J., Kasprzak‐Drozd, K., Niziński, P., Dragan, M., Kondracka, A., Gondek, E., Oniszczuk, T., & Oniszczuk, A. (2024) · Molecules · doi:10.3390/molecules29225245 · Cited by 33
Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH
Zöggeler, T., Kavallar, A. M., Pollio, A. R., Aldrian, D., Decristoforo, C., Scholl‐Bürgi, S., Müller, T., & Vogel, G. F. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2508951 · Cited by 34
Li, Y., Liang, X., Lyu, Y., Wang, K., Han, L., Wang, Y., Sun, J., & Chi, C. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.07.014 · Cited by 34
Zhang, Y., Jiang, W., Xu, J., Wu, N., Wang, Y., Lin, T., Liu, Y., & Liu, Y. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.535940 · Cited by 33
Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis
Zhu, W., Zhou, Y., Tsao, R., Dong, H., & Zhang, H. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.861854 · Cited by 38
The role of the gut microbiome and exercise in non-alcoholic fatty liver disease
Houttu, V., Boulund, U., Grefhorst, A., Soeters, M. R., Pinto‐Sietsma, S., Nieuwdorp, M., & Holleboom, A. G. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820941745 · Cited by 36
Lv, S., Zhang, Z., Su, X., Li, W., Wang, X., Pan, B., Li, H., Zhang, H., & Wang, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1106875 · Cited by 35
Marqués, P., Francisco, V., Martínez‐Arenas, L., Carvalho‐Gomes, Â., Domingo, E., Piqueras, L., Berenguer, M., & Sanz, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032313 · Cited by 32
Tourkochristou, E., Mouzaki, Α., & Triantos, C. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098288 · Cited by 34
Buchynskyi, M., Kamyshna, I., Halabitska, I., Petakh, P., Kunduzova, O., Oksenych, V., & Kamyshnyi, O. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1577724 · Cited by 30
“SCFAs, comprising butyrate, acetate, and propionate, are primarily produced in the colon through microbial fermentation of indigestible complex carbohydrates (dietary fiber) (Furet et al., 2010; Kolodziejczyk et al., 2019).”
Jin, C., Zhou, T., Duan, Z., Deng, Y., Zhang, X., Changyi, X., He, G., He, G., Zhou, Y. H., & Li, S. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116950 · Cited by 30
Panyod, S., Wu, W., Hsieh, Y.-C., Tseng, Y.-J., Peng, S.-Y., Chen, R.-A., Huang, H., Chen, Y., Shen, T. D., Ho, C., et al. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00306-1 · Cited by 33
Kroupova, P., van Schothorst, E. M., Keijer, J., Bunschoten, A., Vodička, M., Irodenko, I., Oseeva, M., Žáček, P., Kopecký, J., Rossmeisl, M., et al. (2020) · Nutrients · doi:10.3390/nu12072037 · Cited by 30
Prins, G. H., Ríos-Morales, M., Gerding, A., Reijngoud, D., Olinga, P., & Bakker, B. M. (2021) · Nutrients · doi:10.3390/nu13124203 · Cited by 30
Genetic regulation of liver lipids in a mouse model of insulin resistance and hepatic steatosis
Norheim, F., Krishnan, K. C., Bjellaas, T., Vergnes, L., Pan, C., Parks, B. W., Meng, Y., Lang, J., Ward, J. A., Reue, K., et al. (2021) · Molecular Systems Biology · doi:10.15252/msb.20209684 · Cited by 32
Li, F., Zhang, Z., Bai, Y., Che, Q., Cao, H., Guo, J., & Su, Z. (2023) · Molecules · doi:10.3390/molecules28196918 · Cited by 29
Emamat, H., Ghalandari, H., Tangestani, H., Abdollahi, A., & Hekmatdoost, A. (2020) · EXCLI journal · doi:10.17179/excli2020-1226 · Cited by 39
Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review
Chen, Y., Wu, W., & Wu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175999 · Cited by 32
Kumar, A. R., Nair, B., Kamath, A. J., Nath, L. R., Călina, D. C., & Sharifi‐Rad, J. (2024) · European journal of medical research · doi:10.1186/s40001-024-02072-3 · Cited by 29
Metadata
- Authors
- Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E.
- Affiliations
- Weizmann Institute of Science (IL)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Tel Aviv Sourasky Medical Center (IL)
- Corresponding author
- Elinav, Eran
- Venue
- EMBO Molecular Medicine
- Published
- 2018-12-27
- Volume
- 11
- Issue
- 2
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC6365925
- OpenAlex
- W2907493655
- Cited by
- 523
- References
- 125
- Citations by year
- 2026: 30 · 2025: 63 · 2024: 73 · 2023: 94 · 2022: 91 · 2021: 76 · 2020: 71 · 2019: 25
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- European Union's Horizon 2020 (747114)
- European Crohn's and Colitis Organization (ECCO) Fellowship
- Ke Lin Program of the First Affiliated Hospital of Sun Yat‐sen University
- Alexander Grass foundation
- Y. and R. Ungar
- Gurwin Family Fund for Scientific Research
- Crown Endowment Fund for Immunological Research
- Else Kroener‐Fresenius Foundation
- Benoziyo Endowment Fund for the Advancement of Science
- Adelis Foundation
- French National Center for Scientific Research
- European Research Council
- Marie Curie Integration grant
- Rising Tide Foundation
- Helmholtz Foundation
- Canadian Institute of Advanced Research
- The Bill & Melinda Gates Foundation & Howard Hughes Medical Institute
- Abisch‐Frenkel Foundation for the Promotion of Life Sciences
- Leona M. and Harry B. Helmsley Charitable Trust
- German–Israeli Foundation for Scientific Research and Development
- Israel Science Foundation
- Minerva Foundation
- European Foundation for the Study of Diabetes
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, gut microbiota, microbiome, cardiometabolic syndrome, obesity, diabetes mellitus, dyslipidemia, hepatic lipid metabolism, hepatic carbohydrate metabolism, inflammation, gut microbiota metabolites, liver cirrhosis, hepatocellular carcinoma
- MeSH terms
- Gastrointestinal Microbiome, Bacteria, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Disease Progression, Carbohydrate Metabolism, Lipid Metabolism, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.